Ligand Pharmaceuticals Short Long Term Debt Total Over Time
| LGND Stock | USD 121.47 1.08 0.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ligand Pharmaceuticals Performance and Ligand Pharmaceuticals Correlation. Ligand |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 2.49 | Revenue Per Share 8.509 | Quarterly Revenue Growth 0.576 | Return On Assets 0.013 |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare Ligand Pharmaceuticals and related stocks such as Passage Bio, Oric Pharmaceuticals, and Lyell Immunopharma Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PASG | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 26.3 M | 21.4 M |
| ORIC | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 2.7 M | 10.2 M | 5.4 M |
| LYEL | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 54.6 M | 67.8 M | 67.7 M | 63.2 M | 61.8 M |
| DSGN | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 3.6 M | 3.6 M | 3.7 M | 3 M | 3 M |
| ASND | 400 K | 400 K | 212 K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 36.6 M | 92 M | 105 M | 508.4 M | 644.3 M | 676.5 M |
| APLS | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 27 M | 157 M | 377.7 M | 210.2 M | 112.7 M | 110.9 M | 164.8 M |
| BGNE | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 13.8 M | 20.8 M | 17.3 M | 164.7 M | 198.4 M | 277.3 M | 562 M | 694.6 M | 891.1 M | 930.2 M | 976.7 M |
| AKRO | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.5 M | 10.9 M | 26.3 M | 27.6 M |
| BPMC | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 9 M | 7.9 M | 4.6 M | 16.3 M | 14.6 M | 95.9 M | 89.6 M | 111.4 M | 562.7 M | 774.1 M | 812.8 M |
| VRDN | 22.6 M | 22.6 M | 22.6 M | 697.1 K | 80 K | 1.1 M | 1 M | 9.9 M | 10.3 M | 8.3 M | 455 K | 520 K | 5.3 M | 21 M | 22.1 M |
| TERN | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 1.2 M | 1.2 M | 603 K | 572.9 K |
| GPCR | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 621 | 260 K | 5.5 M | 5.7 M |
| ETNB | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 20 M | 27.1 M | 24.4 M |
| CRNX | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | 4.8 M | 4.8 M | 4.8 M | 4 M | 3.1 M | 2 M | 51.7 M | 54.3 M |
| CYTK | 1.1 M | 3 K | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 29.9 M | 37 M | 42.4 M | 136.1 M | 138.9 M | 269.9 M | 749.3 M | 755.8 M | 793.6 M |
| RCUS | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 116.9 M | 120 M | 11 M | 10.4 M |
| CGEM | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 3.6 M | 3.5 M |
| ANNX | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 32.9 M | 31.4 M | 26.3 M |
| RLAY | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 178 K | 24.8 M | 24.4 M | 22.9 M | 57.7 M | 53.5 M | 33.6 M |
Ligand Pharmaceuticals and related stocks such as Passage Bio, Oric Pharmaceuticals, and Lyell Immunopharma Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| Ligand Pharmaceuticals Incorporated | LGND |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 121.47
Check out Ligand Pharmaceuticals Performance and Ligand Pharmaceuticals Correlation. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Ligand Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.